Beyond the First SSRI: Augmentation Strategies for Partial Response

When Prozac, Zoloft, Lexapro, Paxil, Celexa, or Luvox helps — but not enough — here’s how psychiatrists think through the next move.

One of the most common scenarios in psychiatric practice isn’t a medication that fails outright — it’s one that works partially. A patient on fluoxetine, sertraline, escitalopram, paroxetine, citalopram, or fluvoxamine reports that their mood is “better, but not really better.” Sleep has improved, but motivation hasn’t returned. Anxiety has eased, but a flat, unmotivated fog has settled in its place. This is a partial response, and it’s one of the most important junctions in depression treatment, because the temptation is simply to raise the dose again and hope. Often, the better move is augmentation: adding a second agent that works through a different mechanism, rather than pushing a single drug past its point of diminishing returns.

Composite Case: “Rachel,” 29

Rachel had been on sertraline 150mg for four months. Her panic attacks were gone and she was sleeping through the night, but she described herself as “a zombie who doesn’t cry anymore, but also doesn’t feel anything good.” This blunted, amotivational presentation — common with long-term SSRI use — is a frequent trigger for augmentation rather than simply increasing dose further.

Below are the augmentation and switching strategies most commonly used when an SSRI gets a patient partway there.

1. Bupropion Augmentation

Adding bupropion (Wellbutrin) to an SSRI is one of the most widely used combinations in psychiatry, and for good reason. Bupropion works on dopamine and norepinephrine rather than serotonin, so it directly counteracts the low-energy, low-motivation, low-libido picture that chronic SSRI use can produce. It’s often the first augmentation tried because it’s generally well tolerated, doesn’t cause weight gain, and can offset SSRI-induced sexual side effects rather than adding to them.

2. Atypical Antipsychotic Augmentation

Low-dose atypical antipsychotics are FDA-approved as adjuncts to antidepressants for treatment-resistant depression. Aripiprazole (Abilify) and brexpiprazole (Rexulti) are the two most frequently reached for, typically at doses far lower than those used for psychotic disorders. Quetiapine XR is another option, particularly when sleep and anxiety remain prominent. These agents work quickly relative to antidepressants, sometimes producing a mood lift within one to two weeks, but they carry their own tradeoffs — akathisia, weight gain, and metabolic risk — that need to be weighed and monitored.

3. Lithium Augmentation

Lithium is one of the oldest and best-studied augmentation strategies in psychiatry, with decades of evidence behind it — including data suggesting it may reduce suicide risk independent of its mood effects. It requires more monitoring than most other options (baseline and periodic renal and thyroid function, along with serum lithium levels), which is part of why it’s used less often than newer agents despite strong efficacy data. It remains a go-to choice in more treatment-resistant cases.

4. Thyroid Hormone (T3) Augmentation

Even in patients with normal thyroid function, adding a small dose of liothyronine (T3) can enhance antidepressant response. The exact mechanism isn’t fully settled, but T3 augmentation has a long track record, notably in the STAR*D trial, where it performed comparably to lithium augmentation with a somewhat gentler side-effect profile. It’s a reasonable option when a patient wants to avoid the monitoring burden of lithium.

5. Mirtazapine Augmentation (“California Rocket Fuel”)

Combining an SSRI or SNRI with mirtazapine (Remeron) is a well-known strategy sometimes nicknamed “California rocket fuel” for its potency. Mirtazapine works on distinct serotonin and norepinephrine receptors, and it’s especially useful when insomnia and appetite loss are part of the picture, since it tends to promote both sleep and appetite. The tradeoff is sedation and weight gain, so it’s best matched to patients who need those particular effects.

6. Buspirone Augmentation

Buspirone is an older anti-anxiety agent that can modestly boost antidepressant response when added to an SSRI, likely through its partial agonism at the serotonin 1A receptor. It’s not as robust an augmentation strategy as some others on this list, but its favorable side-effect profile — minimal sedation, no weight gain, no sexual dysfunction — makes it a reasonable low-risk add-on, particularly in patients who haven’t tolerated other augmentation agents well.

7. Switching Classes Entirely: SNRIs

Sometimes the right answer isn’t to add a second medication, but to switch entirely to an antidepressant with a different mechanism. Venlafaxine XR (Effexor XR) and duloxetine (Cymbalta) act on both serotonin and norepinephrine, which can produce a meaningfully different response in patients who’ve plateaued on a pure SSRI — particularly when fatigue, low motivation, or comorbid pain conditions are part of the presentation. A cross-taper is usually preferred over an abrupt switch to minimize withdrawal and serotonergic symptoms.

Research Note

The STAR*D trial — the largest real-world antidepressant effectiveness study ever conducted — found that after two failed antidepressant trials, remission rates dropped substantially, underscoring why thoughtful augmentation early on matters more than simply cycling through monotherapies indefinitely.

Choosing the Right Strategy

There’s no single correct order to try these in — the right augmentation strategy depends on which symptoms are driving the partial response. Low energy and flat affect point toward bupropion or an SNRI switch. Persistent anxiety and insomnia point toward mirtazapine or buspirone. More severe or chronic resistance points toward lithium, T3, or an atypical antipsychotic. This is why partial response deserves a real conversation with a psychiatrist rather than an automatic dose increase — the next step should match the specific gap between where a patient is and where they need to be.

Rachel, from the case above, was started on bupropion XL augmentation. Within three weeks, her energy and sense of pleasure returned without disrupting the anxiety control she’d already gained from sertraline — a reminder that partial response is often a solvable problem, not a ceiling.

Keywords: SSRI augmentation, partial response to antidepressants, bupropion augmentation, aripiprazole augmentation, lithium augmentation depression, T3 thyroid augmentation, mirtazapine combination, treatment-resistant depression Palm Beach #SSRI #AntidepressantAugmentation #TreatmentResistantDepression #Psychiatry #MentalHealth #PalmBeachPsychiatrist #IntegrativePsychiatry #DepressionTreatment

Struggling with a medication that’s only partly working?

Dr. Mark Agresti offers concierge psychiatric care and statewide Florida telemedicine, with a focus on getting treatment right — not just started.

44 Cocoanut Row, Suite M202, Palm Beach, FL 33480  |  (561) 760-